InnoDiab Forschung GmbH

At InnoDiab Forschung GmbH in Essen, a major focus is on cardiovascular diseases linked to obesity, type 2 diabetes, and chronic kidney disease. The trials are designed to better understand whether new treatments can lower the risk of heart events, protect kidney function, and reduce inflammation-related complications.

• Studies in atherosclerotic cardiovascular disease and heart failure prevention
• Research on chronic kidney disease and systemic inflammation
• Trials evaluating whether new therapies can reduce major cardiovascular events and improve long-term outcomes

This area reflects a strong effort to improve treatment effectiveness for people with overlapping heart, kidney, and metabolic conditions.

The site conducts extensive research in nutritional and metabolic diseases, especially obesity, overweight, and type 2 diabetes. Many studies are testing new therapies to support weight loss, improve blood sugar control, and address related health risks in adults living with excess body weight.

• Trials in chronic weight management and obesity
• Studies in type 2 diabetes mellitus and type 1 diabetes
• Research focused on improving glycemic control and supporting healthier body weight

These studies help evaluate new options for people with metabolic conditions that often occur together and require long-term management.

Another key field at this research facility is respiratory tract diseases, with a strong emphasis on obstructive sleep apnea. The clinical trials are exploring whether emerging therapies can improve breathing-related symptoms, reduce sleep disruption, and support better overall health in people with obesity-related sleep disorders.

• Studies in moderate to severe obstructive sleep apnea among adults with overweight or obesity
• Research on sleep apnea outcomes alongside weight reduction
• Trials aimed at improving symptoms and assessing treatment benefit in respiratory and metabolic overlap conditions

This work connects sleep medicine with metabolic care, reflecting the close relationship between breathing disorders, body weight, and cardiometabolic risk.

The trial portfolio at InnoDiab Forschung GmbH brings together cardiovascular, metabolic, and respiratory research in studies that often include people with more than one condition. The main goal is to test new therapies that may improve weight, blood sugar, sleep-related breathing, and cardiovascular risk at the same time.

• Research in patients with obesity plus type 2 diabetes or cardiovascular disease
• Studies assessing whether new treatments can improve multiple related health outcomes
• Clinical work aimed at better managing common comorbidities linked to excess body weight

With 28 trials and a focused investigator team, the site is contributing to a broad but highly connected research program in cardiometabolic and sleep-related disease.